Support for this idea comes from evidence indicating that KOR antagonists can attenuate withdrawal-related anxiety and other signs of negative affect (Schank et al., 2012; Valdez and Harshberger, 2012; Berger et al., 2013), without altering physical symptoms of dependence (Kissler and Walker, 2015). This evidence concerns the gene OPRK1 and Anxiety.